China NMPA Drug Inspection - Hunan Yuxin Pharmaceutical Co., Ltd - yam

The "Jiangsu Province 2018 First Issue Drug Quality Bulletin," published on March 20, 2018, by the Jiangsu Provincial Food and Drug Administration, highlights significant quality control failures across a range of pharmaceutical products. The bulletin reports findings from inspections of various manufacturers, identifying non-compliant chemical drugs, antibiotics, biochemical drugs, traditional Chinese medicines, and hospital preparations. Numerous companies were cited for violations, including Shandong Sibangde Pharmaceutical Co., Ltd., Jiangsu Pengyao Pharmaceutical Co., Ltd., Anhui Fengyuan Tongling Traditional Chinese Medicine Pieces Co., Ltd., and Nantong Sanyue Traditional Chinese Medicine Pieces Co., Ltd., among many others. The main issues identified covered a broad spectrum of quality deficiencies. For chemical drugs, violations included failures in dissolution, presence of related substances, visible foreign matter, incorrect content determination, and appearance defects, as well as microbial limits and weight variation. Traditional Chinese medicines and prepared pieces frequently exhibited non-compliance related to appearance, content determination, sulfur dioxide residue, total ash, extractives, identification, and moisture. One hospital preparation was also found to have a content weight difference. These deficiencies indicate a failure to adhere to critical regulatory frameworks, primarily the Chinese Pharmacopoeia (2015 and 2010 Editions), various National Food and Drug Administration Standards, Ministry of Health Drug Standards, and the Jiangsu Province Traditional Chinese Medicine Pieces Processing Standards (2002 Edition). Although specific required actions for each company are not detailed in this bulletin, the publication of these findings serves as a public notification, underscoring the necessity for manufacturers to promptly address and rectify these quality control shortfalls to ensure product safety and efficacy. This regulatory action is crucial for maintaining public health and trust in the pharmaceutical supply chain.